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Abstract: Meldonium (3-(2,2,2-trimethylhydrazinium)propionate) is the most potent clinically used inhibitor of organic cation
transporter 2 (OCTN2). Inhibition of OCTN2 leads to a decrease in carnitine and acylcarnitine contents in tissues and energy
metabolism optimization-related cardioprotective effects. The recent inclusion of meldonium in the World Anti-Doping Agency
List of Prohibited Substances and Methods has raised questions about the pharmacokinetics of meldonium and its unusually long
elimination time. Therefore, in this study, the rate of meldonium washout after the end of the treatment was tested with and with-
out administration of carnitine, c-butyrobetaine (GBB) and furosemide to evaluate the importance of competition for OCTN2
transport in mice. Here, we show that carnitine and GBB administration during the washout period effectively stimulated the
elimination of meldonium. GBB induced a more pronounced effect on meldonium elimination than carnitine due to the higher
affinity of GBB for OCTN2. The diuretic effect of furosemide did not significantly affect the elimination of meldonium, carnitine
and GBB. In conclusion, the competition of meldonium, carnitine and GBB for OCTN2-mediated transport determines the phar-
macokinetic properties of meldonium. Thus, due to their affinity for OCTN2, GBB and carnitine but not furosemide stimulated
meldonium elimination. During long-term treatment, OCTN2-mediated transport ensures a high muscle content of meldonium,
while tissue clearance depends on relatively slow diffusion, thus resulting in the unusually long complete elimination period of
meldonium.
Meldonium (3-(2,2,2-trimethylhydrazinium)propionate), a reg-
ulator of glucose and fatty acid metabolism, is used clinically
as a cardioprotective drug [1–3]. At the beginning of 2016,
meldonium was included in the World Anti-Doping Agency
List of Prohibited Substances and Methods. Since then, more
than 100 adverse analytical findings about meldonium have
been recorded [4]. The unusual pharmacokinetics of meldo-
nium was recently outlined [5–7]; however, detailed measure-
ments of meldonium pharmacokinetics in plasma, tissues and
urine after the end of the treatment have not been taken.
For a long time, meldonium was known as the most potent
inhibitor of organic cation transporter 2 (OCTN2) [8], and new
and more active inhibitors have been synthesized only recently
[9]. The main function of OCTN2 is to ensure high tissue con-
tent of organic cations such as carnitine and c-butyrobetaine
(GBB) [10]. Importantly, OCTN2 also ensures the absorption of
organic cations in the ileum and reuptake in kidneys. Thus, the
mechanism of meldonium action is the inhibition of OCTN2,
which leads to carnitine elimination by urine and decreased tis-
sue carnitine content. Recent studies have shown that limited tis-
sue content of carnitine prevents acylcarnitine accumulation
during ischaemia–reperfusion and atherosclerosis and protects
cardiac and vascular tissue against acylcarnitine-induced damage
[11–13]. In addition, decreased acylcarnitine content improves
muscle and heart insulin sensitivity and glucose tolerance [14].
Because meldonium is an organic cation that contains an
N-trimethyl group, it not only inhibits OCTN2-mediated car-
nitine transport but is also effectively transported by OCTN2
[15]. This ensures reuptake of meldonium in kidneys and
transport into tissues, where meldonium competes with car-
nitine and GBB for OCTN2-mediated transport. Although the
higher affinity of meldonium for OCTN2 might suggest a
higher priority for transport, the limited transport capacity of
OCTN2 and transporter saturation must be considered [16].
Thus, OCTN2 can ensure kidney reuptake of organic cations
such as carnitine to maintain its plasma concentration at up to
60 lM; if compounds exceed this concentration, they are
eliminated by urine [17,18]. The highest tissue content
(~1 mM) of carnitine is in the heart, and this could be related
to the higher expression of OCTN2 in cardiac tissue [17]. The
administration of meldonium decreases carnitine transport, but
carnitine might be expected to compete with meldonium and
decrease the transport of meldonium, particularly when meldo-
nium intake is discontinued. In addition, administration of
meldonium stimulates a significant, several times increase in
the plasma GBB concentration [19]. Compared with meldo-
nium (EC50 for OCTN2 of 63 lM), the ability of GBB to
inhibit OCTN2-mediated carnitine transport is approximately
15 times higher [20]. Therefore, GBB must be considered as
an important competitor for meldonium transport. Furosemide
does not inhibit OCTN2 and is used as non-specific control
compound that influences the clearance of many exogenous
and endogenous compounds, including carnitine [21]. There-
fore, this study was designed to characterize the competition
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among meldonium, GBB and carnitine for OCTN2-mediated
transport.
Materials and Methods
Animals. The experimental procedures were carried out in accordance
with the guidelines of the European Community (2010/63/EU), local
laws and policies and were approved by the Latvian Animal
Protection Ethical Committee, Food and Veterinary Service, Riga,
Latvia. All studies involving animals are reported in accordance with
the ARRIVE guidelines [22,23].
Twenty-five male SW mice (6 weeks old, Laboratory Animal Cen-
tre, Institute of Biomedicine and Translational Medicine, Tartu, Esto-
nia) were housed under standard conditions (21–23°C, relative
humidity 50%  10%, 12-hr shifted light–dark cycle) with unlimited
access to food and water. The mice were adapted to local conditions
for 2 weeks before the start of treatment. Meldonium (3-[2,2,2-tri-
methylhydrazinium] propionate dihydrate) was obtained from JSC
Grindeks (Riga, Latvia). Carnitine was purchased from Lonza (Basel,
Switzerland), and c-butyrobetaine hydrochloride (GBB) was obtained
from Sigma-Aldrich (Steinheim, Germany). Furosemide solution was
purchased from Sopharma (Sofia, Bulgaria). Methanol and acetonitrile
were purchased from Merck (Darmstadt, Germany). Heparin sodium
was purchased from Panpharma (Fougeres, France). All compounds
were administered with drinking water. The mice received meldonium
at a dose of 400 mg/kg with drinking water for 2 weeks, and then, all
animals were divided into five groups (five animals per group). One
group was killed after 2 weeks of meldonium treatment; the other
groups received water or GBB at a dose of 200 mg/kg, carnitine at a
dose of 200 mg/kg and furosemide at a dose of 20 mg/kg with drink-
ing water for 1 week. Urine samples were collected 1 and 7 days after
the start of the washout period. At the end of the treatment, the mice
were killed in the morning, and blood plasma, heart and muscle tissue
samples were collected. Urine, plasma and tissue samples were stored
at 20°C prior to analysis.
UPLC/MS/MS assay. The concentrations of carnitine, GBB and
meldonium in plasma, tissue and urine samples were measured using
the UPLC/MS/MS method, as previously described [24]. Sample
preparation involved a simple one-step protein precipitation with
acetonitrile–methanol solution. As an internal standard, we used
3-(2,2-dimethyl-2-prop-1-yl-hydrazinium) propionate for all
calculations. Urine samples were diluted 20 or 1000 times with water
before analysis. Briefly, 100 lL of an acetonitrile–methanol mixture
(3:1, v/v) was added to 25 lL of plasma, tissue homogenate or diluted
urine sample. Samples were centrifuged at 11 000 9 g for 10 min to
precipitate proteins. Then, 60 lL of supernatant was diluted with
500 lL of acetonitrile–methanol mixture (3:1, v/v) containing internal
standard. Samples were injected into the UPLC system (Acquity,
Waters Corp., Manchester, UK). Chromatographic separation was
carried out on a BEH HILIC (1.7 lm, 2.1 9 50 mm) column (Waters
Corp.) at a flow rate of 0.25 mL/min. The composition of the mobile
phase [acetonitrile – 10 mM aqueous ammonium acetate (pH 4)]
varied linearly from 75% to 55% of acetonitrile. Carnitine, GBB and
meldonium were quantified by monitoring the specific transitions for
each compound on the Micromass Quattro Micro instrument (Waters
Corp.). The ion source parameters were as follows: capillary voltage
0.3 kV; source temperature 120°C; desolvation gas temperature
350°C; and desolvation and cone gas flow 500 L/h and 50 L/h,
respectively. The MS/MS transitions (cone voltage; collision energy)
were as follows: 162.20 ? 102.90 Da (25V; 16 eV) for carnitine;
146.20 ? 86.90 Da (25V; 17 eV) for GBB; 147.20 ? 58.30 Da
(20V; 15 eV) for meldonium; and 175.30 ? 86.10 Da (22V; 14 eV)
for IS. The lower limit of quantification was 0.37 nmol/mL for
carnitine, 0.18 nmol/mL for GBB and 0.46 nmol/mL for meldonium.
Applied analytical procedures provided fair separation of all analytes
of interest in one run.
Statistical analyses and calculations. Results are expressed as the
mean  standard error mean (S.E.M.). Statistically significant
differences in the mean values were tested by one-way ANOVA with
Dunnett’s multiple comparison test. The differences were considered
significant when p < 0.05. The data were analysed using GraphPad
Prism 5.0 statistical software (GraphPad Inc., La Jolla, CA, USA).
Results
In this study, a high dose of meldonium (400 mg/kg) was
used to ensure high plasma and tissue levels of meldonium at
the end of the treatment. Administration of meldonium for
14 days significantly elevated its concentration in plasma up
to 320 lM (fig. 1A). The 7-day washout resulted in an
approximately 100 times decrease in the meldonium concen-
tration. In contrast to furosemide administration, carnitine and
GBB stimulated meldonium elimination and decreased concen-
trations of meldonium in plasma by three times compared with
the water control group (fig. 1A).
Meldonium administration induced a significant decrease in
the carnitine plasma concentration (fig. 1B). After the 7-day
washout period, the carnitine plasma concentration was par-
tially restored in the water and furosemide group. In the GBB
group, the carnitine plasma concentration after 1 week was
restored to the control level (table 1), whereas carnitine
administration not only restored the carnitine plasma concen-
tration but induced significant elevation above the control
level.
Consistent with the results of previous studies, administra-
tion of meldonium induced a significant three times increase
in the GBB plasma concentration (table 1). During the wash-
out period, the GBB plasma concentration in the water group
decreased to the control level (1.2  0.11 lM). A similar
decrease was observed in the furosemide group (fig. 1C).
GBB and carnitine administration increased the GBB plasma
concentration by approximately 60 and 40 times compared
with the control level, respectively. Overall, administration of
GBB and carnitine but not furosemide during the washout per-
iod stimulated the elimination of meldonium and restored the
carnitine concentration in plasma.
Similar to the results in plasma samples, administration of
meldonium for 14 days significantly elevated the content of
meldonium in heart tissues up to 5000 nmol/g, which corre-
sponds to an intracellular concentration of approximately
5 mM (fig. 2A). One week of washout resulted in a 15 times
decrease in the meldonium concentration. Furosemide did not
stimulate meldonium elimination. By contrast, both GBB and
carnitine almost completely eliminated meldonium from heart
tissue. Thus, both compounds in 1 week reduced meldonium
content in the heart from 5000 to 18 nmol/g of tissue.
Two-week administration of meldonium induced a 90 times
decrease in carnitine content in heart tissue, and after the
washout period, the carnitine content was restored to control
level in all groups (fig. 2B). Carnitine treatment induced an
increase in heart carnitine content to ~45% above the water
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control level. The increase in the heart carnitine content was
much less pronounced than the increase in the plasma car-
nitine concentration in the carnitine supplementation group.
Meldonium treatment at a dose of 400 mg/kg did not
induce an increase in the heart content of GBB. A high dose
of meldonium stimulated both GBB production and elimina-
tion by urine. In contrast to the minor increase in carnitine
content in the heart, GBB and carnitine administration during
washout induced a substantial increase in the GBB heart con-
tent above the control level (fig. 2C). Thus, the GBB content
was elevated approximately 12 times after GBB administration








































































Fig. 1. Concentrations of meldonium (A), carnitine (B) and GBB (C)
in plasma. Meldonium administration at a dose of 400 mg/kg for
14 days was followed by a 7-day washout period. During the washout
period, water, furosemide (Furosem), GBB and carnitine were admin-
istered in drinking water. All values represent the average of at least
four measurements S.E.M. *significantly different from water control
(one-way ANOVA, Dunnett’s multiple comparison test).
Table 1.
Concentrations of GBB and carnitine in control mice plasma, muscle
and heart tissues.
GBB Carnitine
Plasma, nmol/mL 1.1  0.12 27  2.5
Muscle, nmol/g 12  0.5 169  9
Heart, nmol/g 24  6 941  76















































































Fig. 2. Concentrations of meldonium (A), carnitine (B) and GBB (C)
in heart tissues. Meldonium administration at a dose of 400 mg/kg for
14 days was followed by a 7-day washout period. During the washout
period, water, furosemide (Furosem), GBB and carnitine were admin-
istered in drinking water. All values represent the average of at least
four measurements S.E.M. *significantly different from the water
control (one-way ANOVA, Dunnett’s multiple comparison test).
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induced an approximately six times increase in GBB content
in the heart.
The effects of meldonium treatment and subsequent treat-
ment with and without furosemide, carnitine and GBB in mus-
cle were similar to those observed in heart tissue. The content
of meldonium in muscle after the 2-week treatment was
approximately three times lower than that in the heart. After
1 week of washout, the meldonium content was decreased by
3.4 times (fig. 3A). The decrease was significantly less pro-
nounced in muscle than that in heart and plasma (15 and 100
times, respectively). Similar to the effects observed in the
heart, furosemide did not decrease meldonium content in mus-
cles, whereas administration of GBB and carnitine induced
similar 12 and 10 times decreases, respectively.
Meldonium treatment induced a substantial 34 times
decrease in carnitine content in muscles; however, during
1 week of washout, carnitine content in muscles was restored
to control levels in water, furosemide and GBB groups,
whereas carnitine administration elevated the carnitine content
even two times higher compared with the non-treated control
level (fig. 3B). Meldonium treatment induced a two times
increase in GBB content. During washout, the muscle GBB
content in all groups was significant increased even more
(fig. 3C).
To evaluate the elimination rate of meldonium, the concen-
trations of the compounds in urine were measured. Excess
administered meldonium was eliminated in urine, and at the
end of the 14-day treatment period, the concentration of mel-
donium in urine reached up to 59 mM (table 2). During the
washout period, the meldonium concentration in urine signifi-
cantly decreased to 3943  567 lM on day 1 and to
19  3 lM on day 7 after the end of the treatment (fig. 4A).
Furosemide administration did not influence meldonium elimi-
nation (fig. 4A, B). By contrast, GBB administration signifi-
cantly increased meldonium elimination in urine. The
concentration of meldonium in urine was 5–10 times higher in
the GBB group than in the water group (fig. 4A). Similarly,
carnitine administration also stimulated the elimination of mel-
donium in urine; however, the concentration of meldonium in
urine was lower in the carnitine group than in the GBB group.
The concentration of meldonium was 1.7–7 times higher in
the carnitine group than in the water group, but this difference
was only significant at the end of the washout period (day 7;
fig. 4B).
During meldonium administration, both GBB and carnitine
were eliminated in urine. The GBB concentration in urine
after meldonium administration increased over time, reaching
up to 248  44.6 lM at the end of the 14-day meldonium
treatment period. By comparison, in the control mice, the
GBB concentration in urine was approximately 4.4 lM
(table 2). Excess GBB and carnitine were also eliminated in
urine during the administration of these compounds (fig. 4C).
In vivo, carnitine was partially metabolized to GBB, whereas
GBB was converted to carnitine. The sums of the concentra-
tions of both eliminated compounds were approximately
30 mM in both the GBB and carnitine groups at the end of
the washout period (fig. 4C).
Discussion
In this study, the competition among compounds with differ-
ent affinities for OCTN2 for OCTN2-mediated transport was
investigated in vivo. Here, we show that carnitine and, in
particular, GBB administration during washout effectively
stimulated the elimination of meldonium, similar to the meldo-
nium-induced elimination of carnitine and GBB. The greater
affinity of GBB for OCTN2 resulted in a more pronounced
stimulatory effect on meldonium elimination. In vivo, GBB
was partially converted to carnitine; therefore, GBB, although









































































Fig. 3. Concentrations of meldonium (A), carnitine (B) and GBB (C)
in muscles. Meldonium administration at a dose of 400 mg/kg for
14 days was followed by a 7-day washout period. During the washout
period, water, furosemide (Furosem), GBB and carnitine were admin-
istered in drinking water. All values represent the average of at least
four measurements S.E.M. *significantly different from the water
control (one-way ANOVA, Dunnett’s multiple comparison test).
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carnitine content in heart and muscle. In turn, carnitine stimu-
lated GBB elimination and was metabolized to GBB by the
microbiota, resulting in a significantly increased GBB concen-
tration. The diuretic effect of furosemide did not result in
increased elimination of meldonium, carnitine and GBB.
Recently, it was reported that even 4 weeks after the end of
the treatment, the meldonium plasma concentration was
1.15  0.6 lM in healthy volunteers [5]. This 4-week wash-
out period followed 4 weeks of meldonium treatment at the
clinically suggested dose (500 mg twice a day) [25]. In
addition, the concentrations of meldonium at the end of the
treatment correlated with the concentrations measured after the
washout period, suggesting that the complete elimination time
is longer in individuals who receive higher initial concentra-
tions [25]. In this study, the plasma concentration of meldo-
nium in mice after the end of the treatment decreased
approximately six times faster than in healthy volunteers. This
discrepancy is not surprising because the plasma clearance rate
is faster in rodents than in human beings [26]. However,
mouse muscle clearance was quite similar to that in healthy
volunteers. These data suggest that the pharmacokinetic prop-
erties of meldonium after long-term treatment in mice are sim-
ilar to those in human beings.
The meldonium-induced decrease in the heart carnitine con-
tent can be achieved by increased carnitine elimination by
urine [2]. However, carnitine has a higher affinity for OCTN2,
and therefore, high meldonium doses should be used to ensure
an effective decrease in carnitine levels in plasma and tissue.
Moreover, meldonium is also transported by OCTN2, and
therefore, carnitine stimulates meldonium elimination. GBB, a
precursor of carnitine, has greater affinity for OCTN2 com-
pared with carnitine, and administration of GBB during the
washout period stimulated even faster elimination of meldo-
nium during the first days of treatment. On day 7, however,
the meldonium content in heart and plasma was similar in the
GBB and carnitine groups due to the significant interconver-
sion of GBB and carnitine via GBB and carnitine metabolism
[19]. Thus, the GBB and carnitine concentrations were similar
at day 7, and an unbiased comparison of the effects of GBB
and carnitine on meldonium elimination was therefore possible
only on day 1. In addition, during treatment, meldonium stim-
ulated the biosynthesis of GBB, which then induced meldo-
nium elimination. Overall, higher doses of meldonium should
be used to overcome competition with GBB and carnitine for
transport by OCTN2 and achieve a carnitine-lowering effect.
The main compartments in which compounds compete for
OCTN2 transport are plasma and primary urine. In the wash-
out period, even without GBB and carnitine administration,
increasing plasma concentrations of carnitine stimulate meldo-
nium plasma clearance via elimination in urine. By contrast,
the decrease in meldonium content was significantly slower in
mouse heart and, in particular, muscle than in plasma. More-
over, carnitine and GBB did not directly stimulate meldonium
washout from tissue. In previous studies, the release rate from































































Fig. 4. Concentrations of meldonium (A, B), carnitine and GBB (C)
in urine. Meldonium administration at a dose of 400 mg/kg for
14 days was followed by washout periods of 1 (A) and 7 (B) days.
During the washout period water, furosemide (Furosem), GBB and
carnitine were administered with drinking water. All values represent
the average of at least four measurements S.E.M. *significantly dif-
ferent from the water control (one-way ANOVA, Dunnett’s multiple
comparison test).
Table 2.
Concentrations of meldonium, GBB and carnitine in the urine of non-
treated control and meldonium-treated mice.
Meldonium, lM GBB, lM Carnitine, lM
Control – 4.4  0.3 17  2.3
Meldonium 58562  11700 248  45* 43  8*
Meldonium was administered at a dose of 400 mg/kg for 14 days. All
values represent the average of at least five measurements S.E.M.
*Significantly different from the water control (one-way ANOVA, Dun-
nett’s multiple comparison test).
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slower than OCTN2-mediated carnitine transport into muscle
tissues, and the half-life of release from tissues into plasma is
approximately 139 hr [17,27,28]. The results of this study
confirm that similar to carnitine, more than 90% of the meldo-
nium accumulates in muscles and that meldonium has pro-
longed retention within the muscles. Overall, meldonium
accumulation in the muscles and slow muscle clearance
explain the unusually long complete elimination rate of meldo-
nium.
Due to competition for OCTN2, both endogenous com-
pounds stimulated the elimination of each other; however, at
the end of the experiment, carnitine increased the GBB con-
centration, whereas GBB increased the carnitine concentration
only in plasma and heart tissues. These effects can be
explained by the following mechanisms. Carnitine conversion
to GBB is due to catalysis by the microbiota and enhanced
GBB synthesis from trimethyllysine [19,29]. Both GBB and
carnitine can be metabolized to trimethylamine and its
N-oxide; these compounds are not transported by OCTN2 and
therefore can be quickly eliminated in urine [30]. In this study,
we also observed that an increased concentration of the car-
nitine precursor GBB can effectively increase the carnitine
concentration. Based on the high affinity of GBB for OCTN2,
it would be expected that similar to meldonium, GBB would
induce the elimination of carnitine and subsequent decrease in
carnitine tissue content. Indeed, the carnitine concentration in
the urine was significantly increased during GBB administra-
tion. However, GBB, as a substrate for carnitine synthesis,
completely compensated for the increased carnitine elimina-
tion. These results also confirm that increases in carnitine and
GBB content can be achieved by both GBB and carnitine
administration.
Furosemide is a potent and widely used diuretic drug that
inhibits the Na+-K+-Cl cotransporter in the ascending limb of
the loop of Henle [31]. Furosemide influences the clearance of
many exogenous and endogenous compounds, including car-
nitine [21]. By contrast, a recent study demonstrated that con-
tinuous administration of furosemide increased the renal
expression of organic anion transporter 1 and multidrug resis-
tance protein 2 and decreased p-aminohippurate clearance,
thus significantly elevating the plasma concentration of p-ami-
nohippurate [32]. In this study, furosemide administration dur-
ing the washout period did not result in significantly increased
washout of meldonium, suggesting that furosemide does not
stimulate the elimination of drugs whose reuptake is based on
active transport. In addition, the carnitine and GBB concentra-
tions in plasma and heart tissues were not significantly influ-
enced by furosemide administration. These results indicate that
simultaneous administration of meldonium and furosemide
does not change the pharmacokinetics of meldonium and that
meldonium and furosemide have no significant drug–drug
interactions.
In conclusion, the competition among meldonium, carnitine
and GBB for OCTN2-mediated transport determines the phar-
macodynamics and pharmacokinetics of meldonium. Thus,
due to their affinity for OCTN2, GBB and carnitine but not
furosemide stimulate the elimination of meldonium. During
long-term treatment, OCTN2-mediated transport ensures a
high muscle content of meldonium, whereas tissue clearance
depends on relatively slow diffusion, thus resulting in the
unusually long complete elimination period of meldonium.
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